Basilea Says Phase II Derazantinib Data Keep Drug’s Prospects On Track
Executive Summary
Basilea reported positive interim results from its registrational Phase II study with oncology drug candidate derazantinib in intrahepatic cholangiocarcinoma, or bile duct cancer.
You may also be interested in...
Start-up QED Touts Singular Focus On FGFR Inhibitor Infigratinib
Emerging Company Profile: With backing from BridgeBio, San Francisco start-up QED sees potential for drug licensed from Novartis in a number of tumor types, following the recent presentation of promising results in Phase II for bile duct cancer and Phase I for advanced urothelial cancer.
Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns
Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
Deal Watch: Roche Goes All-In On Real-World Data With Flatiron Acquisition
Already a significant investor in the health care technology firm, buyout will give Roche access to substantial real-world cancer development data. Astellas acquires stem cell-focused Universal Cells.